Home / Stock ratings / Healthcare Stocks / TMO
Stock rating · Measuring & Controlling Devices, Nec
Thermo Fisher Scientific, Inc. (TMO) Stock Rating & Analysis
As of November 20, 2026, MELANY rates Thermo Fisher Scientific, Inc. 58 out of 100 (Very Promising). Its highest factor score is earnings track record at 76, and its lowest is catalyst setup at 36.
TMO · composite score
About Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. As of year-end 2025 it operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (17% of sales), specialty diagnostic products (11%), life science solutions (23%), and lab products and services, which includes CRO services and makes up the remainder.
Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).
Why TMO scores 58/100
TMO's 8 factor scores run from 36 to 76, and 4 of them sit above its composite of 58. Here is how TMO breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 24.1x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 41%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How TMO compares
As of November 20, 2026, Thermo Fisher Scientific, Inc. is tied for 14th of 20 in Healthcare Stocks, where the average score is 62.
Key risks for TMO
- Performance partly driven by Healthcare sector, rotation away from this theme would hurt
Sector and theme context
Thermo Fisher Scientific, Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds TMO's momentum and catalyst factors above.
TMO trade plan (Pro)
MELANY has a full position plan for Thermo Fisher Scientific, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates TMO
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Thermo Fisher Scientific, Inc.'s 58/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about TMO
Is Thermo Fisher Scientific, Inc. (TMO) a buy?
As of 2026-11-20, MELANY rated Thermo Fisher Scientific, Inc. Very Promising with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
How does TMO rank against similar companies?
As of November 20, 2026, Thermo Fisher Scientific, Inc. is tied for 14th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).
Should I buy Thermo Fisher Scientific, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Thermo Fisher Scientific, Inc. (TMO) Very Promising with a composite of 58/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the TMO stock price forecast?
MELANY does not publish price targets or forecasts for TMO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for Thermo Fisher Scientific, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for TMO as of 2026-11-20: its analyst sentiment factor is 73/100, and its price momentum factor is 70/100.
Is TMO stock overvalued or undervalued?
MELANY's valuation factor currently reads 41/100 for Thermo Fisher Scientific, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives TMO's read.
What price should I buy TMO at?
Rather than chasing the current price, MELANY computes a smart entry zone for TMO: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying TMO stock?
The top risks MELANY currently flags for Thermo Fisher Scientific, Inc.: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Thermo Fisher Scientific, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 55/100 for Thermo Fisher Scientific, Inc., and earnings track record, at 76/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will TMO stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 70/100 for TMO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this TMO rating?
The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores TMO as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, TMO included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.